Answers are grounded in this paper and cite their sources.
In systemic lupus erythematosus (SLE), in which autoantibody titers alone do not account for disease activity, the neonatal Fc receptor (FcRn) links their persistence in the circulation to the routing of immune complexes (ICs) and antigen presentation. The recycling of monomeric IgG maintains the pool available to form these complexes, whereas their multivalency engages FcRn in pathways that direct their degradation and the presentation of their autoantigens. It is not the functions themselves, but the cell type in which they operate, that shapes their consequences. This cell dependence results in distinct effects, from the placental transfer of anti-SSA/Ro antibodies to renal clearance or inflammatory functions. Extracellular signals and intracellular mechanisms can locally modulate FcRn expression. Early therapeutic data provide clinical proof of concept in SLE, but the inhibitors evaluated primarily target IgG recycling and transport, without directly elucidating the intracellular handling of ICs. Linking local FcRn expression to IC fate should clarify its contribution to lupus manifestations and the scope of its therapeutic blockade.
No takes yet. Share an insight, caveat, or question.
Ramdani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: